ABUS Arbutus Biopharma Corporation

3.65
+0.00  (0%)
Previous Close 3.65
Open 3.60
Price To book 1.06
Market Cap 200.84M
Shares 55,024,000
Volume 43,019
Short Ratio 8.76
Av. Daily Volume 239,839

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
AB-423 (MAD)
Hepatitis B (HBV)
Phase 2 Cohort 4 data due 3Q 2017.
ARB-1467
Hepatitis B (HBV)
Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
TKM-PLK1
Hepatocellular carcinoma (HCC)

Latest News

  1. Arbutus Presents HBV Drug Combination Studies at ICAR
  2. Moderna Can't Escape My Intellectual Property, Says Arbutus CEO
  3. Edited Transcript of ABUS earnings conference call or presentation 4-May-17 8:30pm GMT
  4. Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  5. Arbutus reports 1Q loss
  6. Arbutus Announces Corporate Update and First Quarter 2017 Financial Results
  7. Investor Network: Arbutus Biopharma Corporation to Host Earnings Call
  8. Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2017 Financial Results
  9. Arbutus Announces ARB-1467 Data Presentation at EASL
  10. Arbutus Injunction Survives Attempted Appeal by Acuitas
  11. Arbutus Announces Appointment of Daniel Burgess to Board of Directors
  12. Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: 2016 By the Numbers : March 23, 2017
  13. Edited Transcript of ABUS earnings conference call or presentation 21-Mar-17 6:00pm GMT
  14. Arbutus Announces Year-End 2016 Financial Results
  15. Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
  16. Alexion Buys LNP Drug Delivery Tech from Arbutus
  17. Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate
  18. Arbutus to Participate in Upcoming Investor Conferences
  19. SBPH: 2016 Results Sustaining Continued HBV/STING Development
  20. Doylestown biopharm firm granted injunction over licensing dispute